Precision Haematological Cancer Medicine

Inbunden, Engelska, 2018

Av Tariq Mughal, UK) Mughal, Tariq (Tufts University Medical Center, Boston, Massachusetts, USA, Kings College NHS Foundation Trust, London, and University of Buckingham Medical School

4 259 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Finns i fler format (1)

Häftad

1 669 kr

Skickas inom 10-15 vardagar

Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.

Produktinformation

Utgivningsdatum2018-10-09
Mått178 x 254 x 18 mm
Vikt453 g
FormatInbunden
SpråkEngelska
Antal sidor242
FörlagTaylor & Francis Ltd
ISBN9781138348424

Tillhör följande kategorier

Hälso- och sjukvård: administration och ledning inom Medicin
Onkologi inom Medicin
Medicinska studiehandledningar och referensmaterial inom Medicin
Hematologi inom Medicin

Tariq I Mughal, MD, FRCP, FACP, graduated in medicine from St George's Hospital Medical School, London, and trained in hematology, medical oncology and stem cell transplantation at the University of Colorado Health Sciences Center, Denver. He is Clinical Professor of Medicine at Tufts University School of Medicine, Boston, Consultant Hematologist at Kings College NHS Foundation Trust, London, Professor of Hematology and Oncology at the University of Buckingham Medical School, UK, and the founder of Apline Oncology Foundation.

Precision Medicine and Future Therapeutics. Classifications and Risk Factors. Historical Milestones. Acute Myeloid Leukaemia. Acute Lymphoblastic Leukaemia. Chronic Myeloid Leukaemia. Myeloproliferative and Related Neoplasms. Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms. Leukaemias of Mature B- and T/NK-Cells. Hodgkin Lymphoma. Non-Hodgkin Lymphoma. Plasma Cell Neoplasms. Principal Treatment-Related Side Effects. Concluding Thoughts.